Interestingly, the insulin-sensitizing PPARγ agonists used for treating type 2 diabetes, such as rosiglitazone and pioglitazone, have proven useful at ameliorating IBD effects in humans with UC [17]. Here, PPARG is linked to type 2 diabetes mellitus.